Newsroom | 2340 results

ROCHESTER, N.Y.--(BUSINESS WIRE)--Token, the next-generation biometric identity assurance company, named Daniel K. Van Ostrand its Head of Engineering and Product. The appointment comes at a defining moment for enterprise security. Credential compromise remains the leading cause of enterprise breaches, and AI has made the problem structurally worse—phishing, deepfakes, and social engineering now operate at machine speed and scale, while the credentials underneath have not fundamentally changed...

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that insights from the LifeVest® wearable cardioverter defibrillator (WCD) helped physicians achieve better heart rate control in female patients – an indicator of more rapid beta-blocker optimization and an outcome associated with improved survival. These findings come from the Optimizing Beta‑Blocker Dosage in Female Patients Using the Wearable Cardiove...

SAN FRANCISCO--(BUSINESS WIRE)--The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) today announced the appointment of John A.T. Young, Ph.D., as Chief Strategy Officer. Dr. Young brings over three decades of distinguished experience spanning academic research, pharmaceutical R&D leadership, and global public health, making him uniquely positioned to advance QBI’s mission of translating cutting-edge protein-protein interaction (PPI) science int...

比利時根特和東京--(BUSINESS WIRE)--(美國商業資訊)-- H.U. Group Holdings Inc.及其獨資子公司Fujirebio今日宣布，Fujirebio Europe N.V.已依據《歐盟(EU) 2017/746體外診斷醫療器材法規》(IVDR)取得Lumipulse G pTau 217血漿檢測試劑盒的CE認證。該化學發光酵素免疫分析(CLEIA)檢測可對人體血漿(K2 EDTA)中的蘇胺酸217磷酸化Tau蛋白(pTau 217)進行量化檢測。 Fujirebio Europe N.V.執行長Christiaan De Wilde表示：「隨著Lumipulse G NfL血液檢測和Lumipulse G pTau 217血漿檢測均在我們的LUMIPULSE G平台完成CE認證，我們正邁入神經診斷的全新時代——憑藉血液生物標記，能夠更早、更廣泛、更便捷地洞察阿茲海默症和神經退化性病變。透過提供全自動和可擴充的解決方案，我們協助臨床醫師更果斷地做出更及時、更明智的決策。這一里程碑印證了我們的長期願景：重塑診斷路徑，並透過創新、精準與合作，從根本上改善歐...

比利时根特和东京--(BUSINESS WIRE)--(美国商业资讯)-- H.U. Group Holdings Inc.及其全资子公司Fujirebio今日宣布，Fujirebio Europe N.V.已依据《欧盟(EU) 2017/746体外诊断医疗器械法规》(IVDR)取得Lumipulse G pTau 217血浆检测试剂盒的CE认证。该化学发光酶免疫分析(CLEIA)检测可对人体血浆(K2 EDTA)中的苏氨酸217磷酸化Tau蛋白(pTau 217)进行定量检测。 Fujirebio Europe N.V.首席执行官Christiaan De Wilde表示：“随着Lumipulse G NfL血液检测和Lumipulse G pTau 217血浆检测均在我们的LUMIPULSE G平台完成CE认证，我们正迈入神经诊断的全新时代——依托血液生物标志物，能够更早、更广泛、更便捷地洞察阿尔茨海默病和神经退行性病变。通过提供全自动和可扩展的解决方案，我们助力临床医师更果断地做出更及时、更明智的决策。这一里程碑印证了我们的长期愿景：重塑诊断路径，并通过创新、精准与合作，从根本上...

GENT, België & TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. en haar volledige dochteronderneming Fujirebio hebben vandaag bekendgemaakt dat Fujirebio Europe N.V. een CE-certificaat heeft verkregen voor de Lumipulse G pTau 217 Plasma-test op grond van Verordening (EU) 2017/746 betreffende in vitro in vitro diagnostische medische hulpmiddelen (IVDR). Deze CLEIA-test (chemiluminescente enzymimmunoassay) maakt de kwantitatieve meting mogelijk van tau gefosforyleerd op threonine 217 (pTau 217) i...

GAND, Belgio, e TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. e la sua controllata al 100% Fujirebio oggi hanno reso noto che Fujirebio Europe N.V. ha ottenuto la certificazione CE per il saggio Lumipulse G pTau 217 Plasma nel quadro del Regolamento (UE) 2017/746 sui dispositivi medico-diagnostici in vitro(IVDR). Questo immunodosaggio enzimatico in chemiluminescenza (CLEIA) consente di quantificare la proteina Tau fosforilata sulla treonina 217 (pTau 217) nel plasma umano (K2 EDTA). "L'otten...

GHENT, Bélgica & TÓQUIO--(BUSINESS WIRE)--A H.U. Group Holdings Inc. e sua subsidiária integral Fujirebio anunciaram hoje que a Fujirebio Europe N.V. obteve o certificado CE para o ensaio Lumipulse G pTau 217 Plasma, nos termos do Regulamento (UE) 2017/746 relativo aos dispositivos médicos para diagnóstico in vitro (IVDR). Este teste CLEIA (imunoensaio enzimático quimioluminescente) permite a medição quantitativa da proteína Tau fosforilada na treonina 217 (pTau 217) no plasma humano (2 EDTA)....

GENT, Belgien & TOKIO--(BUSINESS WIRE)--Die H.U. Group Holdings Inc. und ihre hundertprozentige Tochtergesellschaft Fujirebio gaben heute bekannt, dass Fujirebio Europe N.V. ein CE-Zertifikat für den Lumipulse G pTau 217 Plasma-Assay gemäß der Verordnung (EU) 2017/746 über In-vitro -Diagnostika (IVDR) erhalten hat. Dieser CLEIA-Test (Chemilumineszenz-Enzymimmunoassay) ermöglicht die quantitative Bestimmung von an Threonin 217 phosphoryliertem Tau (pTau 217) in humanem Plasma (K2 EDTA). „Mit den...

GAND, Belgique et TOKYO, Japon--(BUSINESS WIRE)--H.U. Group Holdings Inc. et sa filiale à 100 %, Fujirebio, ont annoncé aujourd’hui que Fujirebio Europe N.V. a obtenu le marquage CE pour le test Lumipulse® G pTau 217 Plasma, conformément au règlement (UE) 2017/746 relatif aux dispositifs médicaux de diagnostic in vitro (IVDR). Ce test CLEIA (dosage immunoenzymatique par chimiluminescence) permet la mesure quantitative de la protéine tau phosphorylée en thréonine 217 (pTau 217) dans le plasma hu...